- 1 Ex vivo susceptibility to antimalarial drugs and polymorphisms
- 2 in drug resistance genes of African Plasmodium falciparum,
- 3 2016-2023: a genotype-phenotype association study
- 4 Jason Rosado<sup>1</sup>\*¥, Abebe A. Fola<sup>2,3</sup>¥, Sandrine Cojean<sup>4,5,6</sup>¥, Véronique Sarrasin<sup>4</sup>¥, Romain
- 5 Coppée<sup>7</sup>, Rizwana Zaffaroulah<sup>4</sup>, Azza Bouzayene<sup>4</sup>, Liliane Cicéron<sup>4</sup>, Ludivine Houzé<sup>4</sup>, Rebecca
- 6 Crudale<sup>2,3</sup>, Lise Musset<sup>8</sup>, Marc Thellier<sup>9</sup>, Bruno Pradines<sup>10,11,12,13</sup>, Jérôme Clain<sup>1</sup>\*¶, Jeffrey A.
- 7 Bailey<sup>2,3</sup>¶, Sandrine Houzé<sup>1,4</sup>¶, Investigation Study Group<sup>∪</sup>
- 8 \(\frac{1}{2}\): The first authors contributed equally to this work.
- 9 ¶: Co-senior authors contributed equally to this work.

## 10 Authors and affiliations

- 11 <sup>1</sup> Université Paris Cité, Institut de Recherche pour le Développement, MERIT, F-75006 Paris,
- 12 France
- <sup>2</sup> Department of Pathology and Laboratory Medicine, Brown University, RI, USA, 02906
- <sup>3</sup> Center for Computational Molecular Biology, Brown University, RI, USA, 02906
- <sup>4</sup> Centre National de Référence du Paludisme, Assistance Publique-Hôpitaux de Paris, Hôpital
- 16 Bichat-Claude-Bernard, Paris, France
- 17 <sup>5</sup> Université Paris-Saclay, Faculté de Pharmacie, Orsay, France
- 18 <sup>6</sup> UMR BIPAR, Anses, Laboratoire de Santé Animale, INRAE, Ecole Nationale Vétérinaire
- 19 d'Alfort, Maisons-Alfort, France
- <sup>7</sup> Université de Rouen Normandie, Laboratoire de Parasitologie-Mycologie, UR 7510 ESCAPE,
- 21 Rouen, France
- <sup>8</sup> Laboratoire de Parasitologie, World Health Organization Collaborating Center for Surveillance
- 23 of Antimalarial Drug Resistance, Centre Nationale de Référence du Paludisme, Institut Pasteur
- de la Guyane, Cayenne, French Guiana
- <sup>9</sup> Centre National de Référence du Paludisme, Sorbonne Université, Assistance Publique des
- 26 Hôpitaux de Paris, Laboratoire de Mycologie et Parasitologie, Hôpital de la Pitié-Salpêtrière,
- 27 Paris, France

33

- 28 <sup>10</sup> Unité Parasitologie et Entomologie, Département des Maladies Infectieuses, Institut de
- 29 Recherche Biomédicale des Armées, Marseille, France
- 30 <sup>11</sup> Aix Marseille Université, SSA, AP-HM, RITMES, Marseille, France
- 31 <sup>12</sup> Centre National de Référence du Paludisme, Marseille, France
- 32 <sup>13</sup> IHU-Méditerranée Infection, Marseille, France
- \*: Corresponding Authors: JR: jjrosados@gmail.com; JC: jerome.clain@u-paris.fr
- 35  $\psi$ : The members of the study group are listed in acknowledgements.
- 37 **Keywords:** Antimalarial drug resistance, *ex-vivo* susceptibility, IC50 assay, genotype

**Abstract** 

62

63

38 **Background:** Given the altered responses to both artemisinins and lumefantrine in Eastern Africa, 39 40 monitoring antimalarial drug resistance in all African countries is paramount. **Methods:** We measured the susceptibility to six antimalarials using ex vivo growth inhibition 41 assays (IC<sub>50</sub>) for a total of 805 Plasmodium falciparum isolates obtained from travelers returning 42 43 to France (2016-2023), mainly from West and Central Africa. Isolates were sequenced using 44 molecular inversion probes (MIPs) targeting fourteen drug resistance genes across the parasite 45 genome. 46 **Findings:** Ex vivo susceptibility to several drugs has significantly decreased in 2019-2023 versus 47 2016-2018 parasite samples: lumefantrine (median IC<sub>50</sub>: 23·0 nM [IQR: 14·4-35·1] in 2019-2023 48 versus 13.9 nM [8.42-21.7] in 2016-2018, p<0.0001), monodesethylamodiaguine (35.4 51·1] versus 20·3 nM [15·4-33·1], p<0·0001), and marginally piperaquine (20·5 [16·5-26·2] 49 50 versus 18.0 [14·2-22·4] nM, p<0·0001). Only four isolates carried a validated *pfkelch13* mutation. 51 Multiple mutations in pfcrt and one in pfmdr1 (N86Y) were significantly associated with altered susceptibility to multiple drugs. The susceptibility to lumefantrine was altered by pfcrt and pfmdr1 52 53 mutations in an additive manner, with the wild-type haplotype (pfcrt K76-pfmdr1 N86) exhibiting 54 the least susceptibility. 55 **Interpretation:** Our study on *P. falciparum* isolates from West and Central Africa indicates a low prevalence of molecular markers of artemisinin resistance but a significant decrease in 56 57 susceptibility to the partner drugs that have been the most widely used since a decade -lumefantrine 58 and amodiaguine. These phenotypic changes likely mark parasite adaptation to sustained drug 59 pressure and call for intensifying the monitoring of antimalarial drug resistance in Africa. 60 Funding: This work was supported by the French Ministry of Health (grant to the French National Malaria Reference Center) and by the Agence Nationale de la Recherche (ANR-17-CE15-0013-61

03 to JC). JAB was supported by NIH R01AI139520. JR postdoctoral fellowship was funded by

Institut de Recherche pour le Développement.

# Research in context

64

65 66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

prompted us to conduct this study.

**Evidence before this study** Artemisinin-based combination therapies (ACTs) have been introduced since the 2000s as the first-line curative treatment of malaria. ACTs combine an artemisinin derivative, which rapidly reduces parasite load, with another antimalarial drug -known as partner drug- which eliminates the remaining parasites thanks to its longer half-life. This approach reduces the likelihood of parasites developing resistance to both drugs, thereby increasing treatment efficacy and delaying the emergence of resistance. However, resistance to artemisinins and then to some partner drugs was identified in Southeast Asia more than a decade ago and has spread throughout the region. Artemisinin partial resistance is now emerging in the East and Horn of Africa. It manifests as delayed parasite clearance from the bloodstream after treatment, increasing the parasite load in contact with the partner drug only and the likelihood of selecting resistant parasites. It is, therefore, important to monitor antimalarial drug susceptibility and drug resistance mutations in contemporary African isolates, especially in the understudied West and Central African regions, to anticipate the spread of multidrug-resistant parasites. We searched for articles on antimalarial drug resistance published between January 1, 2000, and July 1, 2024, using the PubMed search terms "antimalarial resistance", "Africa", and "ex vivo". Of the 69 published studies, only six encompassing a total of 827 isolates across five West and Central African countries from 2016 to 2022 combined ex vivo drug assays with genotyping data. Parasites with an increased rate of ex vivo survival to artemisinins were reported in one study from Ghana (7/90 isolates in 2018) and another from The Gambia (4/41 isolates in 2017). Only the Ghanaian study reported mutations in the non-propeller domain of pfkelch13 gene, whereas the Gambian study reported mutations associated with reduced susceptibility to lumefantrine (7%, 3/41). In Mali, Senegal and Burkina Faso, most isolates were susceptible to commonly used antimalarial drugs (chloroquine, amodiaquine, piperaquine, mefloquine, lumefantrine and dihydroartemisinin) using standard growth inhibition assays. In Ghana, reduced susceptibility to artemisinin, mefloquine and amodiaquine was observed. The relative lack of recent data on parasite susceptibility to antimalarial drugs in recent parasites from West and Central Africa

Added value of this study 94 Ex vivo susceptibility to six antimalarial drugs (dihydroartemisinin, lumefantrine, mefloquine, 95 chloroquine, monodesethylamodiaquine, and piperaquine) and mutations in fourteen drug 96 97 resistance genes were evaluated in 805 isolates collected between January 2016 and February 2023 98 from 35 African countries, mainly from West and Central Africa. 99 Median IC<sub>50</sub> values were in the low nanomolar range, indicating good potency against P. falciparum. However, worrying trends emerged from 2019 onwards, with median IC<sub>50</sub> values for 100 101 lumefantrine that increased from 13.9 nM in 2016-18 to 23 nM in 2019-23 and for amodiaguine 102 from 20.3 nM to 35.4 nM. 103 The high prevalence of resistance alleles in pfdhfr, pfdhps, pfmdr1 and pfcrt genes underscores the sustained pressure exerted by antimalarial drugs on parasite populations. Notably, although the 104 105 triple mutant pfdhfr N51I-C59R-S108N was highly prevalent, the dhfr-dhps quintuple mutant 106 (with extra pfdhps A437G-K540E), which is responsible for sulfadoxine-pyrimethamine treatment 107 failure in adults and children, was rare. In addition, the analysis revealed some geographic and 108 temporal variations in mutation prevalence. 109 The genotype-phenotype association analysis performed in this study elucidates the relationship 110 between genetic variants and ex vivo drug susceptibility, providing valuable information for 111 understanding the molecular basis of resistance and informing future treatment strategies. For 112 example, mutations in the pfcrt and pfmdrl genes, mainly K76T and N86Y, were associated with 113 altered susceptibilities to most drugs. Haplotypic association analysis further indicated that the two 114 genes have cumulative effects on the susceptibility to lumefantrine, with the wild-type haplotype 115 (pfcrt K76-pfmdr1 N86) exhibiting the least susceptibility. Implication of all the available evidence 116 117 While the susceptibility to most antimalarials suggests continued efficacy, the observed decrease in susceptibilities to lumefantrine and amodiaquine in parasites from West and Central Africa from 118 119 2019 onwards suggests an ongoing adaptation of parasites, possibly related to the increasing use 120 of ACT treatments in Sub-saharan Africa since a decade. These phenotypic changes over time 121 were accompanied by small changes in the prevalence of resistance alleles in pfcrt and pfmdrl 122 genes. Additional changes, potentially leading to larger decreases in drug susceptibilities, can be expected over time. The large-scale analysis presented here provides invaluable, contemporary insights into the current landscape of susceptibility to antimalarial drugs and molecular markers of resistance in *P. falciparum* isolates from West and Central Africa. While the data suggests that ACTs and sulfadoxine-pyrimethamine are likely to be effective in these regions, the phenotypic changes we observed call for intensifying the monitoring of antimalarial drug resistance in Africa.

## Introduction

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Malaria continues to take a heavy toll on public health in Africa. Antimalarials remain a cornerstone in the fight against malaria, and the evolution of drug resistance poses a significant threat to the efficacy of treatment regimens.<sup>1,2</sup> Monitoring antimalarial drug resistance and treatment efficacy is paramount, as drug selection pressures are ongoing, and no alternatives to current first-line treatments will be available in the coming years.<sup>3,4</sup> Artemisinin-based combination therapies (ACTs) as first-line curative treatments that were introduced in the 2000s. ACTs combine an artemisinin derivative, which rapidly reduces parasite load, with another antimalarial drug -known as partner drug- which eliminates the remaining parasites thanks to its longer half-life. However, the emergence of artemisinin partial resistance (ART-R) has raised concerns about the long-term efficacy of ACTs for effective malaria treatment.<sup>5,6</sup> After ART-R emerged, treatment failures with dihydroartemisinin (DHA)- piperaquine (PPQ) were reported in Southeast Asia as parasites acquired additional resistance to PPO.<sup>7,8</sup> ART-R has recently emerged in East Africa and the Horn of Africa, 9-11 creating the potential for selection of parasites resistant to the partner drug(s) and threatening the long-term efficacy of ACTs in Africa. 12,13 Worryingly, decreased susceptibility of P. falciparum isolates to the partner drug lumefantrine (LMF) has also been reported in northern Uganda. 14,15 In West and Central Africa, treatment efficacy studies have confirmed the clinical efficacy of ACTs in several settings overall. 16,17 However, few studies have reported ex vivo antimalarial drug assays for West and Central African isolates, with little evidence of reduced susceptibility to partner drugs. 18,19 Molecular surveillance has also revealed the sporadic presence of validated ART-R pfkelch13 mutations in these two regions.<sup>20</sup> To better understand the current situation in West and Central Africa, we analyzed the ex vivo susceptibility to six drugs (DHA, LMF, mefloquine (MFQ), chloroquine (CQ), monodesethylamodiaquine (MDAQ), and PPQ; assessed by growth inhibition assays) of 805 P. falciparum isolates collected between 2016 and 2023 from imported malaria cases in returned travelers to mainly West and Central Africa. The isolates were also sequenced using highthroughput molecular inversion probes (MIPs) targeting 815 overlapping targets across fourteen drug resistance genes to determine the prevalence of drug resistance markers and to estimate genetic correlates of drug susceptibility phenotypes.

# Methods

158

159

### Sample and data collection

- 160 The French National Malaria Reference Center (FNMRC) coordinates a nationwide network of
- hospitals in mainland France to survey imported malaria. Blood samples from civilian or military
- hospitals participating in the FNRMC network were sent to the FNRMC reference laboratory
- 163 (Bichat Hospital in Paris) (see Study Group). Inclusion criteria were: diagnosis of *P. falciparum*
- malaria recorded between January 2016 and February 2023 and confirmed by microscopy and
- PCR, available DNA sample, information on the country visited, and available IC<sub>50</sub> data against
- 166 CQ, MFQ, PPQ, MDAQ, LMF and DHA. A total of 813 isolates fulfilled the inclusion criteria.

#### 167 Ex vivo assays

- 168 CQ, DHA, MDAQ, MFQ, LMF, and PPQ were purchased from Alsachim (Illkirch Graffenstaden,
- 169 France). The susceptibility of the isolates to the antimalarial drugs was assessed without culture
- adaptation. 100 µL of parasitized erythrocytes (final parasitaemia of 0.5% and a final hematocrit
- of 1.5%) were aliquoted into 96-well plates preloaded with a concentration gradient of antimalarial
- drugs. The plates were incubated for 48 hours in a controlled atmosphere of 85% N<sub>2</sub>, 10% O<sub>2</sub>, 5%
- 173 CO<sub>2</sub> at 37°C. Drug susceptibilities were determined as half-maximal inhibitory concentrations
- 174 (IC<sub>50</sub>s) using the standard 42-hour [<sup>3</sup>H]hypoxanthine uptake inhibition assay (**Supplementary**
- 175 **Methods**) <sup>21</sup>. Resistance thresholds for the six compounds were previously reported by Pradines,
- 176 Kaddouri and others. 22–24

177

185

### DNA extraction and MIP sequencing of drug resistance genes

- 178 Genomic DNA was extracted from 200 µL whole blood using a MagNA Pure automaton (Roche
- Diagnostics, USA), eluted in 100 μL, and stored at -20°C. DNA extracts from the included samples
- 180 were sent to Brown University for MIP sequencing. All samples were then genotyped using
- molecular inversion probes (MIPs, n=815) targeting known drug resistance SNP mutations in 14
- genes across the *P. falciparum* genome, as previously described (**Table S1, Appendix 2**). 12,25
- Sequencing was performed on an Illumina NextSeq 550 instrument (150 bp paired-end reads) at
- 184 Brown University (RI, USA).

### MIP data analysis and estimating drug resistance prevalence

187 Sequencing data processing and variant calling were performed using MIPtools (v0.19.12.13;

https://github.com/bailey-lab/MIPTools). The prevalence for each drug resistance marker was

calculated as p = x / n \* 100, where p is the prevalence, x is the number of infections with mutant

alleles, and n is the number of successfully genotyped infections, as previously described. <sup>12</sup> Mixed

genotypes, i.e. a sample with a reference allele and an alternative allele in a given sample, were

considered mutant regardless of the within-sample mutant allele frequency. Haplotypes were

reconstructed for all samples using the major allele in a given codon (Supplementary Methods).

### Phenotype-genotype association analysis

- 195 Isolates with >30% missing genotype data were discarded. We then retained only biallelic non-
- synonymous SNPs with minor allele frequency (MAF) >0.01 for phenotype-genotype association
- analysis. Phenotype-genotype association was performed with the SNPassoc R package (v.2.1.0)
- 198 <sup>26</sup> using the built-in WGassociation function under a dominant model. For each drug, a linear
- 199 regression model was fitted with continuous IC<sub>50</sub> values as the outcome and individual SNP
- 200 genotypes as independent variables. The model was adjusted for the complexity of infection (COI),
- year, and the visited country of imported cases as covariates.

### Ethical aspects

186

188

189

190

191

192

193

194

202

211

- 203 Informed consent was not required because the clinical and biological data were collected from
- the FNMRC database by the common public health mission of all National Reference Centers in
- France, in coordination with the Santé Publique France organization for malaria surveillance and
- care. According to article L1221–1.1 of the Public Health Code in France, the study was considered
- 207 non-interventional research and only required the patient's non-opposition (according to article
- 208 L1211–2 of the Public Health Code). All data were anonymized before use. The FNMRC got the
- authorization to use their databases according to the National Data Protection Commission (CNIL)
- 210 (number 1223103). Human DNA was not analyzed.

### Role of the funding source

- The funders of the study had no role in design, data collection, data analysis, data interpretation,
- 213 or writing of the report.

### Results

214

215

229

### Geographical origin and year of collection

From January 2016 to February 2023, 1,126 P. falciparum isolates from travelers were evaluated 216 217 for ex vivo antimalarial drug susceptibility at the FNMRC laboratory. Of these, 813 isolates were 218 included in this study, corresponding to samples with validated IC<sub>50</sub> for the following six drugs: 219 DHA, LMF, MFQ, MDAQ, CQ, and PPQ. According to reported travel history, infections 220 originated from thirty-five African countries, but most isolates were from travelers who had visited 221 West (59%, 471/805) and Central (38%, 306/805; Figure 1A) African countries. The most visited 222 countries were Côte d'Ivoire (27%, 217/805), Cameroon (21%, 169/805), Mali (9%, 69/805), 223 Guinea (7%, 58/805), and Republic of the Congo (6%, 45/805) (Figure 1A and Table S2). The 224 number of samples collected per year was higher in 2016 (165/805), 2017 (166/805) and 2018 225 (167/805) than in 2019 (100/805) and beyond (Figure 1B). No differences were seen in the 226 distribution of countries between 2016-2018 and 2019-2023 (p>0.05, **Table S3**). Travelers were 227 predominantly male (62%), with a median age of 40 years and a median parasitemia of 1.7% 228 (Table 1).

### Half-maximal inhibitory concentration (IC<sub>50</sub>) for six antimalarial compounds

- 230 IC<sub>50</sub> values of *P falciparum* 3D7 laboratory reference strain are indicated in **Table S4**. For the
- isolates tested in this study, the median IC<sub>50</sub> estimated with the standard growth inhibition assay was less than 30 nM for all assessed antimalarial compounds, consistent with potent activity. The
- 233 median IC<sub>50</sub> values for the six drugs were 1·1 nM [IQR: 0·8-1·7] for DHA, 16·7 nM [9·9-27·4]
- 234 for LMF, 29·5 nM [19·1-45·5] for MFQ, 23·4 nM [17·1-39·0] for MDAQ, 26·7 nM [18·0-41·2]
- for CQ, and 18.5 nM [15.1-24.3] for PPQ. Using published resistance thresholds, <sup>22-24</sup> 49% of the
- isolates were classified as resistant to MFQ ( $IC_{50} > 30 \text{ nM}$ ), 10% to CQ ( $IC_{50} > 100 \text{ nM}$ ), and 3% to MDAQ
- 237 (IC<sub>50</sub> > 80 nM). Less than 1% of isolates had an IC<sub>50</sub> above the threshold for DHA (10 nM), LMF (150 nM)
- 238 and PPQ (135 nM) (**Figure S1**).
- Remarkably, when compared to samples collected in 2016-2018, a significant decrease in
- susceptibility was observed in 2019-2023 samples for LMF (median IC<sub>50</sub>: 13·9 nM [IQR: 8·42-
- 241 21·7] in 2016-2018 versus 23·0 nM [14·4-35·1] in 2019-2023; p<0·001), MDAQ (20·3 nM [15·4-
- 242 33·1] versus 35·4 nM [21·2-51·1]; p<0·001), and modestly for PPO (18·0 nM [14·2-22·4] versus
- 243 20.5 [16.5-26.2]; p<0.001) (**Figure 2, Table S5**). In contrast, a modest improvement in

- susceptibility was observed in 2019-2023 samples for CQ (27·7 nM [19·0-45·0] versus 25·1 nM
- 245 [17·3-38·9]; p=0·05), and there was no significant change for MFQ. Altered drug susceptibilities
- between the two time periods were again detected after data stratification into West and Central
- 247 African countries, except for DHA, which was significantly altered only in samples from Central
- Africa, and for CQ (**Table S6**), possibly because of less power for CQ. We note that these temporal
- changes in drug susceptibility were not significant when using 1-year bins during the 2016-2023
- study period (**Table S7**). The frequency of CQ-resistant isolates ( $IC_{50} > 100 \text{ nM}$ ) decreased nearly
- 251 by half in 2019-2023 compared to 2016-2018 (7% in 2019-2023 versus 12% in 2016-2018,
- 252 p<0.05) (**Table S8**).
- 253 There were several significant drug-drug IC<sub>50</sub> correlations, most of which were positive (**Figure**
- S2). The largest positive correlations involved the following drug pairs: LMF-MFQ, CQ-MDAQ,
- 255 DHA-LMF, and DHA-MFQ. The negative correlations were much less intense and involved CQ-
- 256 LMF and CQ-MFQ.

#### Prevalence of validated antimalarial resistance mutations

- 258 Sequence data generated with MIPs covered 43 exons from 14 genes reported to be associated
- 259 with drug resistance. 805 out of the 813 included isolates were successfully genotyped. The
- average number of reads per sample was 120 (range: 48-258) (Figure S3). Nearly 60% of the
- isolates (477/805) had a COI >1. We first examined the prevalence of mutations in five robustly
- validated drug resistance genes: *pfdhfr* and *pfdhps* (associated with resistance to pyrimethamine
- and sulfadoxine, respectively), pfcrt and pfmdr1 (associated with multidrug resistance), and
- 264 *pfkelch13* (associated with ART-R).
- 265 More than 85% of isolates carried the *pfdhfr* N51I, C59R, and S108N mutations (**Figure 3A**),
- 266 which were predominantly found as the IRN triple mutant haplotype and marginally as the ICN
- and NRN double mutants (Figure S4), regardless of the country of infection (Figure S5, Table
- 268 **S9**). We found a low prevalence of the *pfdhps* I431V (8.5%), K540E (6%), A581G (8%) and
- 269 A613S (15%) mutations, and a large prevalence of S436A and A437G (53% and 78%,
- 270 respectively). At pfdhps codons 436-437-540-581 considered jointly (haplotypes, Figure S4),
- single mutants AAKA and SGKA were the most common haplotypes (35% and 50% respectively).
- 272 The quintuple mutant dhfr+dhps haplotype IRN+A437G-K540E, which is responsible for SP
- treatment failure in adults and children, was detected in 3% of samples (19/600).

- In pfmdr1, the prevalence of the N86Y, Y184F, D1246Y mutations were 11%, 71%, and 1%,
- 275 respectively (Fig 3A), and the prevalence of the NYD, NFD and YFD haplotypes at codons 86-
- 276 184-1246 were 38·8%, 54·8% and 5·6%, respectively (**Figure S4**). Other minor haplotypes were
- found in less than 1% of isolates.
- 278 The *pfcrt* K76T mutation was found in 30% of isolates (**Figure 3A**) and was absent in the Central
- 279 African Republic (**Figure S5**). Regarding the classical eight *pfcrt* codons 74-75-76-220-271-326-
- 280 356-371, three main haplotypes were detected (Figure S4; per country, see Table S10 and Figure
- **S6**): the wild-type MNKAQNIR (77%) and the mutants **IETSENTI** (also known as Cam783;
- 282 15%) and **IETSENII** (also known as GB4; 6%).
- Four isolates carried a validated *pfkelch13* mutation in the propeller domain (**Figure 3B**): A675V
- 284 (2/734, from Rwanda in 2019 and Uganda in 2020), Y493**H** (1/705, from Mali in 2016), and I543**T**
- 285 (1/731, from Côte d'Ivoire in 2018). The two isolates carrying the A675V mutation showed a
- susceptibility to DHA (IC<sub>50</sub> = 1.78 nM and IC<sub>50</sub> = 1.67 nM) larger than the upper quartile. The
- 287 A675V isolate from Rwanda also had elevated IC<sub>50</sub> values for LMF (IC<sub>50</sub> = 41.57 nM) and MFQ
- 288 (IC<sub>50</sub> =  $49 \cdot 12$  nM). Two other mutations were detected in the propeller domain: A578S (8 isolates)
- 289 that is known as a polymorphism and E612D (1 isolate). Most of the other non-synonymous
- 290 pfkelch13 mutations occurred in the N-terminal-coding domain (Figure 3B, Figure S7), K189T
- being very frequent (58·4%) and also known as polymorphism.
- 292 Finally, the prevalence of "background" mutations associated with ART-R in South East Asia <sup>27</sup>
- 293 was low: pffd D193Y at 0·27%, pfmdr2 T484I at 0%, pfpib7 C1484F at 0·16%, and pfpp V1157L
- 294 at 0% (**Table S11**).
- We then analysed mutation prevalence over time (Figure 3C, Figures S8 and S9, and Table S12).
- Remarkably, when compared to samples collected in 2016-2018, a significant decrease in
- 297 prevalence was observed in 2019-2023 samples for *pfcrt* K76T (33% in 2016-2018 versus 25% in
- 298 2019-2023; p<0.05) and pfmdr1 N86Y (14% versus 5%; p<0.001), and there was a nearly
- significant decrease for *pfmdr1* Y184F (73% versus 66%; p=0·07) (Figure 3C). The prevalence
- of the wild-type haplotype at pfcrt 76 and pfmdr1 86 (K76-N86) was largely dominant across the
- 301 whole study period and slightly increased from 73% in 2016-2018 to 79% in 2019-2023 (p=0.05,
- 302 Figure 3D, Figure S8B). Analysis of SNP-SNP correlation in isolates from Côte d'Ivoire and

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Cameroon indicated that pfmdr1 N86Y and pfcrt K76T were not in linkage disequilibrium with each other (Figure S10). Association between SNPs and drug susceptibility Genotype-phenotype association analysis across 362 SNPs and susceptibilities to 6 drugs showed several significant associations (Figure 4, Tables S12 for the full list of associations, and S13 and **S14** after correction for multiple testing). Most strikingly, multiple well-known SNPs in *pfcrt* were strongly associated with susceptibilities to multiple drugs (CQ, MDAQ, DHA, LMF) and were borderline significant after multiple testing correction for MFQ and PPQ. Mutant pfcrt alleles were associated with decreased susceptibility to CQ ( $p = 10^{-38} - 10^{-50}$  for 7 amino acids) and MDAQ  $(p = 10^{-6} - 10^{-8})$  for 7 amino acids) whereas wild-type pfcrt alleles were associated with decreased susceptibility to DHA ( $p = 10^{-6}$  for 6 amino acids) and LMF ( $p = 10^{-5}$  for 3 amino acids). There was also a strong association between the well-characterised mutation N86Y in pfmdr1 and susceptibility to MFO ( $p = 10^{-6}$ ), LMF ( $p = 10^{-5}$ ), and DHA (p = 0.0003, although non-significant after correction). Finally, the pfubp1 N1704K and K1705N mutations were associated with decreased susceptibility to CQ ( $p = 2 \cdot 10^{-5}$  and  $0 \cdot 0001$  respectively). To control for the major pfcrt effect, we added pfcrt K76T as a covariate (**Table S13**). All the associations involving another SNP in pfcrt (except M74I for CQ) and pfubp1 N1704K and K1705N were lost, suggesting they were dependent on the pfcrt K76T genotype. The associations involving pfmdr1 (with LMF and MFQ) were maintained and no new associations were detected. A model with pfmdr1 N86Y as a covariate abolished only the association of pfubp1 K1705N for CQ (but not the one of N1704K) (**Table S13**). These data indicate that, among the 362 tested SNPs, pfcrt and pfmdr1 SNPs were the major drivers of susceptibility to most tested drugs and could interact in a likely additive manner in the case of LMF. Effect of *pfcrt* and *pfmdr1* haplotypes on IC<sub>50</sub>s As compared to the wild-type pfcrt (MNKAQNIR), mutant haplotypes IETSENTI and IETSENII (that differ at I356T only) were significantly associated with decreased susceptibility to CQ and MDAQ (Kruskal-Wallis test, p-value range: <0.0001-0.0003; Figure S11) and improved susceptibility to DHA, LMF and PPQ (Kruskal-Wallis test, p-value range: <0.0001- 0.05). **IETSENTI**, but not **IETSENII**, was associated with improved susceptibility to MFQ (Kruskal-

Wallis test, p = 0.0001), suggesting that I356T has some role in MFQ transport activity.

Isolates carrying the *pfmdr1* NYD wild-type haplotype had decreased susceptibility to DHA, LMF,

MFQ and improved susceptibility to PPQ as compared to the mutant YFD (Kruskal-Wallis test,

p-value range: <0.001 - 0.01; **Figure S11**).

Finally, the analysis of *pfcrt* K76T - *pfmdr1* N86Y haplotypes identified three main drug patterns

(Figure 5). The susceptibility to LMF, MFQ, and also marginally to DHA, improved with the

number of pfcrt-pfmdr1 mutations suggesting these mutations work in additive ways. The most

decreased susceptibility to LMF was associated with the wild-type haplotype (pfcrt K76-pfmdr1

N86). The susceptibility to CQ and MDAQ decreased mostly with mutant pfcrt, and the addition

of mutant pfmdr1 had a lesser effect. The susceptibility to PPQ was more difficult to interpret with

little haplotypic effects.

# Discussion

333

334

335

336

337

338

339

340

341

342

343

345

346

347

348

349

350

351

352

353

354

355

357

358

359

360

361

Whereas there are recent reports of emerging ART-R and decreased susceptibility to LMF in *P*.

falciparum parasites from East Africa, <sup>28</sup> few recent studies have investigated the resistance status

of contemporary West and Central African isolates at a large scale. Here, we report the temporal

trends of ex vivo susceptibilities to six antimalarials using standard growth inhibition assays and

their association with mutations in fourteen drug resistance genes in 805 P. falciparum samples

collected between 2016 and 2023 in returned travelers to West and Central African countries. We

found an overall excellent susceptibility of isolates to the six evaluated antimalarials, but the one

to ACT partner drugs LMF and MDAQ decreased in recent years. Concomitantly, the prevalence

of wild-type pfcrt K76 and pfmdr1 N86 alleles increased in recent years, consistent with a large

selective pressure exerted by the use of LMF and the discontinuation of CQ in these regions.

Finally, altered susceptibility to most drugs was strongly associated with pfcrt and/or pfmdr1

genotypes.

Regarding molecular ART-R, only four isolates among 805 carried a WHO-validated pfkelch13

mutation. A675V was detected in two travelers returning from East Africa (Rwanda and Uganda),

consistent with the spread of this mutation in this region. 10,29 The returned traveler from Uganda

showed delayed clearance under artesunate therapy, 30 whereas the A675V isolate from Rwanda,

had elevated IC<sub>50</sub> values for LMF (41.57 nM) and MFQ (49.12 nM), consistent with clinical and

ex vivo data reported by others for Ugandan A675V isolates. 11,14,15 Two other validated mutations,

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389 390

391

Y493H and I543T, were identified in one isolate from Mali in 2016 and one from Côte d'Ivoire in 2018, respectively. These isolates did not have unusual IC<sub>50</sub>s against any of the drugs tested. As these two mutations were not detected in more recent samples, these seem to be sporadic cases. Altogether, pfkelch13 ART-R mutations were detected but uncommon in Central and West African isolates during the study period (2016-2023). Contrary to the current situation in East Africa, pfkelch13-mediated ART-R is seemingly not emerging during 2016-2023 in West and Central African regions. Continuous monitoring of *pfkelch13* mutations should however be reinforced as they could either emerge locally or be introduced in these regions by intracontinental migration from East Africa. We found a significant reduction in susceptibility of *P. falciparum* to LMF and MDAQ for samples collected in recent years. LMF and MDAQ are the two main partner drugs used in West and Central Africa during the last decade. The use of ACTs may have selected parasites whose response to the partner's drug is altered in these regions. A similar trend was previously reported for LMF in northern Uganda, <sup>14</sup> which possibly predated the emergence of ART-R in this region. <sup>10</sup> The clinical effects of the decreased susceptibilities to LMF and MDAQ observed in our study are unknown, but the spread of ART-R may be facilitated in such phenotypic backgrounds. Remarkably, wild-type pfcrt and pfmdrl genes were individually associated with decreased susceptibility to LMF, consistent with previous in vitro and clinical findings. <sup>31,32,33</sup> Haplotypic association analysis further suggests that the two genes have cumulative effects, with the wildtype haplotype (pfcrt K76-pfmdr1 N86) exhibiting the largest decrease in susceptibility to LMF. The increasing prevalence in recent years of parasites carrying the wild-type allele at either gene or at both could, therefore, explain the LMF data. In contrast the double mutant haplotype (pfcrt 76T-pfmdr1 86Y) exhibited the largest decrease in susceptibility to MDAQ. Taken together, these findings support the rationale for implementing regimens with drug combinations that exert opposing selective pressures.<sup>34</sup> Of note, susceptibility to MDAQ decreased in recent years, whereas the prevalence of the pfcrt K76T mutation decreased slightly. This is surprising as this mutation is strongly associated with decreased susceptibility to MDAQ in our dataset and other studies. We have no solid explanation for this result, but one possibility could be that other mediators of altered susceptibility to MDAQ exist and that our targeted MIP sequencing and association studies did not capture them.

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

Intriguingly, two novel pfubp1 mutations, N1704K and K1705N, were associated with reduced susceptibility to CO in our data set. The effect of these pfubp1 mutations seems to depend on the pfcrt K76T genotype. However, as these two mutations have low prevalence (10.0 and 7.9%, respectively) and likely a modest effect, we have low statistical power to conduct a haplotypic analysis. Several studies reported an association of different upb1 mutations with altered survival or susceptibility to DHA in mouse malaria or P. falciparum, 35,14 and recently to MFQ, LMF and PPQ in the *Plasmodium yoelii* mouse malaria model.<sup>36</sup> However, as the two new mutations are located in an N/K repeat protein region that is not part of the reported active site(s) of the enzyme, gene editing experiments are needed to formally address their role in modulating drug response to CO.37The high prevalence of pyrimethamine resistance mutations in the study period indicates the high level of SP pressure in West and Central Africa. Nevertheless, the low prevalence of pfdhps K540E (<10%) and of the SP-resistant quintuple dhfr-dhps mutant (3%) is reassuring that SP is still effective for preventive therapies. Indeed, the WHO recommends for countries to withdraw SP for IPTp use when the prevalence of *Pfdhps* K540E>95% and A581G>10% and for IPTi use when the prevalence of *Pfdhps* K540E >50%.<sup>38</sup> This study was not conducted without limitations. First, we have not evaluated ex vivo resistance to artemisinin derivatives with the dedicated ring survival assay, the standard measure of in vitro susceptibility to artemisinins. We, however, report very rare ART-R mutations in pfkelch13, and at this time, these are the major determinants of ART-R in patients. Second, we have not evaluated copy number variations in pfmdr1 and pfplasmepsins 1-2 that are associated with altered susceptibility to MFQ and PPQ, respectively. Third, our geographical coverage of West and Central Africa is biased, with two countries contributing to almost 50% of the total isolate sampling (169 isolates from Cameroon in Central Africa and 217 isolates from Côte d'Ivoire in West Africa). Therefore, trends at the country level could not be robustly drawn. Fourth, our analyses focused on imported malaria cases to France and infections in travelers may differ in several aspects from those in people living in endemic areas. Finally, we used a targeted sequencing approach to genotype isolates and focused on validated and some candidate drug resistance genes. Detecting emerging resistance mutations in novel genes would need a larger genomic coverage.

- 421 In conclusion, our study provides much-needed information on molecular and phenotypic
- 422 resistance in contemporary isolates from West and Central Africa. It shows how current and past
- 423 control efforts have been affecting malaria parasite populations in those regions and calls for
- 424 intensifying the monitoring to inform as quickly as possible on future changes regarding
- 425 antimalarial drug susceptibilities and resistance.

# Author contributions

426

432

- JR, AAF, SC, VS, RCo, JC, JAB, and SH designed the study. SC, VS, RZ, AB, LC, and LH did
- 428 the ex-vivo IC<sub>50</sub> assays, and archived data. LM, MT, BP, JC and SH provided administrative and
- 429 logistical support. JR, AAF, JC, RCr, and JAB analysed and did the genotyping. JR and AAF
- verified and analysed the data and did the statistical analysis. All authors had full access to all the
- data. All authors contributed to the writing of the manuscript.

# Acknowledgements

- We thank the participants who anonymously agreed to participate in a malaria drug resistance
- surveillance study in France, the staff at the CNR for their support in collecting isolates and
- 435 executing the drug resistance test, Justine Bailly at MERIT unit, and Alec Leonetti's MIP
- 436 sequencing support at Brown University. The members of the French National Reference Centre
- for Imported Malaria Study Group are as follows: Dr A. Aboubacar (CHU Strasbourg), Dr P.
- 438 Agnamey (CHU Amiens), Dr A. Ahmed (CHU Strasbourg), Dr D. Ajzenberg (CHU Limoges), Dr
- 439 A. Angoulvant (CHU Bicetre), Dr F. Ariey (CHU Cochin, Paris), Dr B. Aubry (CH Le Mans), Pr
- 440 F. Banisadr (CHU Reims), Dr S. Belaz (CHU Pontchaillou Rennes), Dr G. Belkadi (CHU Saint
- 441 Antoine, Paris), Dr A. Bellanger (CHU Jean Minjoz,-Besancon), Dr D. Bemba (CHU Jean Verdier,
- Bondy), Dr F. Benaoudia (CH Troyes), Dr J. Benjamin Murat (CH Roanne), Dr M. Bloch (CHU
- 443 Louis Mourier, Colombes), Dr F. Botterel (CHU Henri Mondor, Créteil), Dr V. Bouden (CH Saint-
- 444 Nazaire), Dr M. Bougnoux (CHU Necker Enfants Malades, Paris), Dr C. Brump (CHU
- Lariboisière, Paris), Dr S. Brun (CHU Avicenne, Bobigny), Dr J. Brunet (CHU Strasbourg), Dr B.
- 446 Buret (CH Niort), Dr P. Caraux-Paz (CH Villeneuve St Georges), Dr N. Celine (CHU Clermont
- 447 Ferrand), Dr A. Cherif Touil (CH Niort), Dr S. Clauser (CHU Ambroise Paré, Boulogne
- 448 Billancourt), Dr E. Collin (CH R Ballanger, Aulnay sous-bois), Dr N. Dahane (CHU Cochin,
- Paris), Dr C. Damiani (CHU Amiens), Dr E. Dannaoui (CHU HEGP, Paris), Dr C. Dard (CHU
- 450 Grenoble), Pr M. Darde (CHU Limoges), Dr L. De Gentile (CHU Angers), Dr A. Debourgogne
- 451 (CHU Nancy), Dr T. Delacour (CH Creil), Dr J. Delarbre (CH Mulhouse), Dr A. Delaval (CH R
- 452 Ballanger, Aulnay sous-bois), Dr V. Delcey (CHU Lariboisière, Paris), Dr A. Deleplancque (CHU
- 453 Lille), Dr G. Desoubeaux (CHU Bretonneau, Tours), Dr G. Desoubeaux (CHU Tours), Dr N.
- 454 Desuremain (CHU Armand Trousseau, Paris), Dr G. Dewulf (CH Valenciennes), Dr R. Durand
- 455 (CHU Avicenne, Bobigny), Dr M. Durieux (CHU Limoges), Dr E. Dutoit (CHU Lille), Dr M.

456 Edith (CH Valenciennes), Dr O. Eloy (CH André Mignot, Le Chesnay), Dr M. Evrard Sylvie (CH 457 Villeneuve St Georges), Dr J. Faucher (CHU Limoges), Pr L. Favennec (CHU Ch,Pr A. Fave 458 (CHU Robert Debre, Paris), Dr O. Fenneteau (CHU Robert Debre, Paris), Dr C. Ficko (Hia Begin, Saint-Mandé), Dr E. Frealle (CHU Lille), Dr R. Gabrielle (CH Tourcoing), Dr G. Gargala (CHU 459 460 Rouen), Dr C. Garnaud (CHU Grenoble), Dr N. Godineau (CH Delafontaine, Saint-Denis), Dr J. Gorlicki (CHU Lariboisière, Paris), Dr A. Gravet (CH Mulhouse), Dr N. Guennouni (CHU Bicetre, 461 462 Le Kremlin Bicêtre), Dr S. Hamane (CHU Saint-Louis, Paris), Dr T. Hanslik (CHU Ambroise 463 Paré, Boulogne Billancourt), Dr A. Huguenin (CHU Reims), Dr J. Hurst (CH Jacques Monod, Le 464 Havre), N. Imbert (APHP, Hôpital Bichat-Claude-Bernard), Dr F. Jeddi (CHU Nantes), Dr L. 465 Jordan (CHU Lille), Dr L. Landraud (CHU Louis Mourier, Colombes), Dr H. Lapillonne (CHU 466 Armand Trousseau, Paris), Dr S. Larréché (Hia Begin, Saint-Mandé), Dr R. Lavergne (CHU 467 Nantes), Dr Y. Le Govic (CHU Angers), Dr G. Le Moal (CHU Poitiers), Dr J. Lemoine (CHU 468 Angers), Dr C. Leprince (CH R Ballanger, Aulnay sous-bois), Dr E. Lesteven (CHU Lariboisière, 469 Paris), Dr A. Li (CH Creil), Dr C. Lohmann (CH Mulhouse), Dr B. Louise (CHU Dijon), Dr M. 470 Machouart (CHU Nancy), Dr C. Malassigne (CH Le Havre), C. Maréchal (APHP, Hôpital Bichat-471 Claude-Bernard), Dr A. Marteau (CHU Avicenne, Bobigny), Dr D. Maubon (CHU Grenoble), Dr 472 E. Mazars (CH Valenciennes), Pr B. Megarbane (CHU Lariboisière, Paris), Dr A. Mendes-Moreira 473 (CH La Rochelle), Dr S. Mermond (GH La Rochelle), C. Moissant, (APHP, Hôpital Bichat-474 Claude-Bernard), Dr A. Moreno (CHU Saint Antoine, Paris), Dr P. Mornand (CHU Armand 475 Trousseau, Paris), Dr J. Murat (CHU Limoges), Dr R. Nabias (CH Poissy/Saint-Germain-En-476 Laye), Dr J. Naudin (CHU Robert Debre, Paris), Dr G. Nevez (CHU Brest), Pr G. Nevez (CHU 477 La Cavale Blanche, Brest), Dr C. Nourrisson (CHU Clermont-Ferrand), Dr M. Oussama (CHU 478 Pitié Salpetrière, Paris), Dr N. Dr P. Patoz (CH Tourcoing), Pean-De-Ponfilly (CHU Lariboisière, 479 Paris), Dr J. Peltier (CH Poissy/Saint-Germain-En-Laye), Dr P. Penn (CH Le Mans), Dr A. 480 Perignon (CHU Pitié Salpetrière, Paris), Dr E. Perraud-Cateau (CHU Poitiers), Dr A. Pfaff (CHU Strasbourg), Dr M. Pihet (CHU Angers), Dr P. Poirier (CHU Clermont Ferrand), Dr J. Pilo (Hia 481 482 Begin, Saint-Mandé), Dr I. Poilane (CHU Jean Verdier, Bondy), Dr D. Poisson (CH Orléans), Dr 483 D. Pons (CHU Clermont Ferrand), Dr L. Pull (CHU Robert Debre, Paris), Dr D. Quinio (CHU Brest), Dr D. Raffenot (CH Chambery), Dr M. Revest (CHU Pontchaillou, Rennes), Dr G. Robert 484 (CHU Grenoble), Dr O. Rogeaux (CH Chambery), Dr M. Sasso (CHU Caremeau Nimes), Dr F. 485 486 Schmitt (CH Mulhouse), Dr B. Sendid (CHU Lille), Dr Y. Senghor (Groupe Hospitalier Saint Joseph, Paris), Dr M. Silva (CH Jacques Monod, Le Havre), Dr J. Siriez (CHU Robert Debré, 487 488 Paris), Dr E. Sitterlé (CHU Necker Enfants Malades, Paris), Dr F. Sorge (CHU Necker Enfants Malades, Paris), Dr I. Tantaoui (CHU Pitie-Salpetriere, Paris), G. Thaboulet (APHP, Hôpital 489 490 Bichat-Claude-Bernard), Dr D. Toubas (CHU Reims), Dr C. Tournus (CH Saint-Denis), L. Wallus, 491 (APHP, Hôpital Bichat-Claude-Bernard), Dr H. Yera (CHU Cochin, Paris).

## Conflict of interest

492

493

The authors declare no conflicts of interest.

# Data availability

494

502

- All sequencing data are available under accession no. SAMN42141774 to SAMN42142576 at the
- 496 Sequence Read Archive (SRA), and the associated BioProject ID is PRJNA1129163. De-identified
- 497 datasets generated during the current study and used to make all figures are available as
- 498 supplementary files or tables. The data and R scripts developed in this study were deposited in the
- 499 GitHub repository (https://github.com/jrosados/CNR IC50 MIPs). Additional software packages
- and tools that are useful when working with MIP data are available at <a href="https://github.com/bailey-">https://github.com/bailey-</a>
- 501 <u>lab/MIPTools</u> and <u>https://github.com/Mrc-ide/mipanalyzer</u>.

## References

- 503 1 Ménard D, Khim N, Beghain J, *et al.* A Worldwide Map of *Plasmodium falciparum* K13-504 Propeller Polymorphisms. *N Engl J Med* 2016; **374**: 2453–64.
- Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. *Nat Rev Microbiol* 2024; published online Feb 6. DOI:10.1038/s41579-024-01008-2.
- 508 3 Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? *Lancet Infect Dis* 2019; **19**: e338–51.
- Watson OJ, Gao B, Nguyen TD, *et al.* Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study. *Lancet Microbe* 2022; **3**: e701–10.
- 513 5 Phyo AP, Nkhoma S, Stepniewska K, *et al.* Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet* 2012; **379**: 1960–6.
- Noedl H, Se Y, Schaecher K, *et al.* Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 2008; **359**: 2619–20.
- 517 7 Amaratunga C, Lim P, Suon S, *et al.* Dihydroartemisinin-piperaquine resistance in
  518 *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet*519 *Infect Dis* 2016; **16**: 357–65.
- 520 8 Leang R, Taylor WRJ, Bouth DM, *et al.* Evidence of *Plasmodium falciparum* Malaria Multidrug Resistance to Artemisinin and Piperaguine in Western Cambodia:
- 522 Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. *Antimicrob*
- 523 Agents Chemother 2015; **59**: 4719–26.
- 524 9 Uwimana A, Legrand E, Stokes BH, *et al.* Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda.
- 526 Nat Med 2020; **26**: 1602–8.
- 527 10 Conrad MD, Asua V, Garg S, et al. Evolution of partial resistance to artemisinins in malaria

- 528 parasites in Uganda. *N Engl J Med* 2023; **389**: 722–32.
- 529 11 Balikagala B, Fukuda N, Ikeda M, *et al.* Evidence of Artemisinin-Resistant Malaria in Africa. 530 *N Engl J Med* 2021; **385**: 1163–71.
- 531 12 Fola AA, Feleke SM, Mohammed H, *et al. Plasmodium falciparum* resistant to artemisinin and diagnostics have emerged in Ethiopia. *Nat Microbiol* 2023; **8**: 1911–9.
- 533 13 Mihreteab S, Platon L, Berhane A, *et al.* Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. *N Engl J Med* 2023; **389**: 1191–202.
- 535 14 Tumwebaze PK, Conrad MD, Okitwi M, *et al.* Decreased susceptibility of *Plasmodium* 536 *falciparum* to both dihydroartemisinin and lumefantrine in northern Uganda. *Nat Commun* 2022; **13**: 1–12.
- van Schalkwyk DA, Pratt S, Nolder D, *et al.* Treatment Failure in a UK Malaria Patient
   Harboring Genetically Variant *Plasmodium falciparum* From Uganda With Reduced In Vitro
   Susceptibility to Artemisinin and Lumefantrine. *Clin Infect Dis* 2024; **78**: 445–52.
- 541 16 Marwa K, Kapesa A, Baraka V, *et al.* Therapeutic efficacy of artemether-lumefantrine, 542 artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of 543 uncomplicated *Plasmodium falciparum* malaria in Sub-Saharan Africa: A systematic review 544 and meta-analysis. *PLoS One* 2022; **17**: e0264339.
- Ishengoma DS, Mandara CI, Bakari C, *et al.* Evidence of artemisinin partial resistance in
   North-western Tanzania: clinical and drug resistance markers study. bioRxiv. 2024;
   published online Feb 1. DOI:10.1101/2024.01.31.24301954.
- 548 18 Mbye H, Mane K, Diop MF, *et al. Plasmodium falciparum* merozoite invasion ligands, linked 549 antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia. *J* 550 *Antimicrob Chemother* 2022; **77**: 2946–55.
- 551 19 Somé AF, Conrad MD, Kabré Z, et al. Ex vivo drug susceptibility and resistance mediating
   552 genetic polymorphisms of *Plasmodium falciparum* in Bobo-Dioulasso, Burkina Faso.
   553 Antimicrob Agents Chemother 2024; 68: e0153423.
- 554 20 Ndwiga L, Kimenyi KM, Wamae K, *et al.* A review of the frequencies of *Plasmodium* 555 *falciparum* Kelch 13 artemisinin resistance mutations in Africa. *Int J Parasitol Drugs Drug* 556 *Resist* 2021; **16**: 155–61.
- 557 21 Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J. Assessment of the drug 558 susceptibility of *Plasmodium falciparum* clinical isolates from africa by using a Plasmodium 559 lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for 560 precise measurement of the 50-percent inhibitory concentration. *Antimicrob Agents* 561 *Chemother* 2006; **50**: 3343–9.
- Pascual A, Madamet M, Briolant S, *et al.* Multinormal in vitro distribution of *Plasmodium falciparum* susceptibility to piperaquine and pyronaridine. *Malar J* 2015; **14**: 49.
- 564 23 Kaddouri H, Djimdé A, Dama S, *et al.* Baseline in vitro efficacy of ACT component drugs on *Plasmodium falciparum* clinical isolates from Mali. *Int J Parasitol* 2008; **38**: 791–8.
- 566 24 Pradines B, Tall A, Rogier C, et al. In vitro activities of ferrochloroquine against 55


- Senegalese isolates of *Plasmodium falciparum* in comparison with those of standard antimalarial drugs. *Trop Med Int Health* 2002; **7**: 265–70.
- 569 25 Aydemir O, Janko M, Hathaway NJ, *et al.* Drug-Resistance and Population Structure of 570 *Plasmodium falciparum* Across the Democratic Republic of Congo Using High-Throughput 571 Molecular Inversion Probes. *J Infect Dis* 2018; **218**: 946–55.
- 572 26 González JR, Armengol L, Solé X, *et al.* SNPassoc: an R package to perform whole genome association studies. *Bioinformatics* 2007; **23**: 644–5.
- 574 27 Miotto O, Amato R, Ashley EA, *et al.* Genetic architecture of artemisinin-resistant *Plasmodium falciparum. Nat Genet* 2015; **47**: 226–34.
- Rosenthal PJ, Asua V, Bailey JA, *et al.* The emergence of artemisinin partial resistance in Africa: how do we respond? *Lancet Infect Dis* 2024; published online March 26. DOI:10.1016/S1473-3099(24)00141-5.
- 579 29 van Loon W, Oliveira R, Bergmann C, *et al.* In Vitro Confirmation of Artemisinin Resistance 580 in *Plasmodium falciparum* from Patient Isolates, Southern Rwanda, 2019. *Emerg Infect Dis* 581 2022; **28**: 852–5.
- 582 30 Coppée R, Bailly J, Sarrasin V, *et al.* Circulation of an Artemisinin-Resistant Malaria 583 Lineage in a Traveler Returning from East Africa to France. *Clin Infect Dis* 2022; **75**: 1242– 584 4.
- 585 31 Dhingra Satish K., Gabryszewski Stanislaw J., Small-Saunders Jennifer L., *et al.* Global Spread of Mutant PfCRT and Its Pleiotropic Impact on *Plasmodium falciparum* Multidrug Resistance and Fitness. *MBio* 2019; **10**: 10.1128/mbio.02731–18.
- 588 32 Sisowath C, Petersen I, Veiga MI, *et al.* In Vivo Selection of *Plasmodium falciparum*589 Parasites Carrying the Chloroquine-Susceptible pfcrt K76 Allele after Treatment with
  590 Artemether-Lumefantrine in Africa. *J Infect Dis* 2009; **199**: 750–7.
- Windle ST, Lane KD, Gadalla NB, *et al.* Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a *Plasmodium falciparum* cross. *Int J Parasitol Drugs Drug Resist* 2020; **14**: 208–17.
- van der Pluijm RW, Tripura R, Hoglund RM, *et al.* Triple artemisinin-based combination
   therapies versus artemisinin-based combination therapies for uncomplicated *Plasmodium falciparum* malaria: a multicentre, open-label, randomised clinical trial. *Lancet* 2020; 395:
   1345–60.
- 598 35 Borrmann S, Straimer J, Mwai L, *et al.* Genome-wide screen identifies new candidate 599 genes associated with artemisinin susceptibility in *Plasmodium falciparum* in Kenya. *Sci* 600 *Rep* 2013; **3**: 1–10.
- 36 Xu R, Lin L, Jiao Z, *et al.* Deaggregation of mutant Plasmodium yoelii de-ubiquitinase UBP1 alters MDR1 localization to confer multidrug resistance. *Nat Commun* 2024; **15**: 1774.
- Singh BK, Zhang C, Wu J, *et al.* A *Plasmodium falciparum* RING Finger E3 Ubiquitin Ligase Modifies the Roles of PfMDR1 and PfCRT in Parasite Drug Responses. *Antimicrob Agents Chemother* 2023; **67**: e0082122.

38 Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamine-resistant *Plasmodium* falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep 2017; : 7389. 

**Table 1.** Epidemiological characteristics of travelers returning to France and description of isolates from 2016 - 2023

Participant characteristics	n = 805
Age, median [IQR]	39.2 [27.1, 51.40]
Sex, n (%)	
Female	306 (38.0%)
Male	499 (62.0%)
Isolates characteristics	
Parasitemia* % (Parasites / 100 RBC), median [IQR]	1.70 [0.81, 3.46]

IQR: Interquartil range; RBC: Red blood cells. \* Missing data for two isolates.



**Figure 1. Geographical origin and collection year of isolates. A)** Map of Africa showing the origin of malaria cases imported into France. Colors indicate sample size, and countries with fewer than three isolates are not shown. **B)** Bar plot showing the temporal distribution of imported malaria cases included in this study.





Figure 2. Half-maximal inhibitory concentration (IC<sub>50</sub>) for six antimalarial drugs. A) Distribution of IC<sub>50</sub> for the six antimalarial drugs in 2016-18 and 2019-23. Box plots show the median IC<sub>50</sub> (in nM) and interquartile range. Change in susceptibility over time was tested by Mann-Whitney test. P-values were adjusted using Benjamini-Hochberg correction.



**Figure 3. Prevalence of key mutations associated with resistance to different drugs. A)** Prevalence of key mutations in *pfcrt*, *pfdhfr*, *pfdhps* and *pfmdr1* genes detected in isolates from this study. **B)** Prevalence of mutations in the *pfkelch13* gene. Green bar plots indicate the prevalence of mutations in the N-terminal-coding domain, while orange bar plots indicate the prevalence of mutations in the propeller domain. SNPs marked with an asterisk (\*) are validated or candidate SNPs by WHO. **C)** Prevalence of the main key mutations in *pfcrt* and *pfmdr1* over time. **D)** Prevalence of *pfcrt* 76-*pfmdr1* 86 haplotypes over time. Color code for the 4 haplotypes: purple, wild-type K76-N86; green, single mutant K76-86Y; blue, single mutant 76T-N86; red, double mutant 76T-86Y. P-values were calculated by Fisher's exact test.





Figure 4. Manhattan plot showing the significance of SNPs associated with six antimalarial drugs. Each dot represents 1 of 362 SNPs with MAF>0·01 colored by chromosome. The x-axis represents the chromosomal location of the SNPs, and the y-axis represents the -log10 of the P-value obtained from the linear regression model analysis. The blue line represents the nominal P-value ( $P \le 0.05$ ), and the red line represents the P-value after Bonferroni correction ( $P \le 1 \times 10^{-4}$ ). The full list of SNPs associated with IC50 is shown in **Table S13**.



**Figure 5. Effect of** *pfcrt* **76-pfmdr1 86 haplotypes on IC**<sub>50</sub> **for six drugs.** A) IC<sub>50</sub> for mefloquine (MFQ), lumefantrine (LMF) and dihydroartemisinin (DHA) disaggregated by *pfcrt-pfmdr1* haplotypes. B) IC<sub>50</sub> for chloroquine (CQ), monodesethylamodiaquine (MDAQ) and piperaquine (PPQ) disaggregated by *pfcrt-pfmdr1* haplotypes. Haplotypes were built with *pfcrt* K76T and *pfmdr1* N86Y using the major allele per position. n: number of isolates carrying the haplotype. Differences in the IC<sub>50</sub> of wild-type (WT|WT, crt-K76|mdr1-N86) versus single mutants (Mut|WT, crt-76T|mdr1-N86), (WT|Mut, crt-K76|mdr1-86Y), and double mutant (Mut|Mut, crt-76T|mdr1-86Y) were calculated with a Pairwise Wilcoxon tests with Benjamini-Hochberg correction. \*: p<0.05; \*\*: p<0.001.